Telmipres
Generic Name
Telmisartan
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| telmipres 20 mg tablet | ৳ 6.00 | ৳ 60.00 |
Description
Overview of the medicine
Telmipres 20 mg tablet contains Telmisartan, an angiotensin II receptor blocker (ARB) used to treat high blood pressure (hypertension) and to reduce the risk of cardiovascular events such as heart attack and stroke in high-risk patients.
Uses & Indications
Dosage
Adults
The usual recommended dose is 40 mg once daily. For Telmipres 20 mg, it may be used as an initial dose or for maintenance in some patients. Dosage can be increased to a maximum of 80 mg once daily if necessary.
Elderly
No dosage adjustment is necessary for elderly patients.
Renal_impairment
No dosage adjustment is necessary for patients with mild to moderate renal impairment. Caution should be exercised in severe renal impairment.
How to Take
Telmipres 20 mg Tablet should be taken orally once daily, with or without food. It should be swallowed whole with water.
Mechanism of Action
Telmisartan selectively blocks the binding of angiotensin II to the AT1 receptor in various tissues, including vascular smooth muscle and the adrenal gland. This blockage prevents angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation, decreased systemic vascular resistance, and ultimately a reduction in blood pressure.
Pharmacokinetics
Onset
Antihypertensive effect begins within 3 hours; maximum effect generally observed after 4-8 weeks of therapy.
Excretion
Almost exclusively excreted in feces via bile, mainly as unchanged drug. Less than 1% is excreted in urine.
Half life
Approximately 24 hours.
Absorption
Rapidly absorbed from the gastrointestinal tract. Peak plasma concentration occurs within 0.5-1 hour. Absolute bioavailability is approximately 42% for a 40 mg dose and 58% for a 160 mg dose.
Metabolism
Primarily metabolized by conjugation to form an acylglucuronide, which is pharmacologically inactive. No evidence of cytochrome P450 involvement.
Side Effects
Contraindications
- Hypersensitivity to telmisartan or any component of the tablet.
- Pregnancy (especially 2nd and 3rd trimesters).
- Biliary obstructive disorders.
- Severe hepatic impairment.
- Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73 m²).
Drug Interactions
Digoxin
Increased plasma concentrations of digoxin may occur; monitor digoxin levels.
Lithium
Reversible increases in serum lithium concentrations and toxicity have been reported; monitor lithium levels carefully.
Aliskiren
Concomitant use with aliskiren is contraindicated in diabetic patients or patients with renal impairment (GFR <60 mL/min/1.73 m²) due to increased risk of hypotension, hyperkalemia, and renal impairment.
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
May reduce the antihypertensive effect of telmisartan and increase the risk of renal impairment, especially in dehydrated or elderly patients.
Potassium-sparing diuretics/Potassium supplements
May lead to increased serum potassium levels (hyperkalemia).
Storage
Store in a dry place below 30°C, protected from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include hypotension, dizziness, and tachycardia or bradycardia. Treatment is symptomatic and supportive. Telmisartan is not removed by hemodialysis.
Pregnancy & Lactation
Telmipres is contraindicated in the second and third trimesters of pregnancy due to the risk of fetal injury or death. It is not recommended during the first trimester. It is also not recommended during breastfeeding due to the potential for adverse effects on the nursing infant.
Side Effects
Contraindications
- Hypersensitivity to telmisartan or any component of the tablet.
- Pregnancy (especially 2nd and 3rd trimesters).
- Biliary obstructive disorders.
- Severe hepatic impairment.
- Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73 m²).
Drug Interactions
Digoxin
Increased plasma concentrations of digoxin may occur; monitor digoxin levels.
Lithium
Reversible increases in serum lithium concentrations and toxicity have been reported; monitor lithium levels carefully.
Aliskiren
Concomitant use with aliskiren is contraindicated in diabetic patients or patients with renal impairment (GFR <60 mL/min/1.73 m²) due to increased risk of hypotension, hyperkalemia, and renal impairment.
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
May reduce the antihypertensive effect of telmisartan and increase the risk of renal impairment, especially in dehydrated or elderly patients.
Potassium-sparing diuretics/Potassium supplements
May lead to increased serum potassium levels (hyperkalemia).
Storage
Store in a dry place below 30°C, protected from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include hypotension, dizziness, and tachycardia or bradycardia. Treatment is symptomatic and supportive. Telmisartan is not removed by hemodialysis.
Pregnancy & Lactation
Telmipres is contraindicated in the second and third trimesters of pregnancy due to the risk of fetal injury or death. It is not recommended during the first trimester. It is also not recommended during breastfeeding due to the potential for adverse effects on the nursing infant.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24-36 months from the date of manufacture, consult product packaging for exact date.
Availability
Pharmacies, Hospitals
Approval Status
Approved
Patent Status
Patent expired for Telmisartan
Clinical Trials
Telmisartan has been extensively studied in various clinical trials, demonstrating its efficacy and safety in managing hypertension and reducing cardiovascular risk in diverse patient populations, including the ONTARGET and TRANSCEND studies.
Lab Monitoring
- Regular monitoring of blood pressure.
- Monitoring of serum potassium levels, especially in patients with renal impairment or those taking potassium-sparing diuretics.
- Assessment of renal function (e.g., serum creatinine, GFR) periodically.
Doctor Notes
- Counsel patients on the importance of consistent medication adherence for optimal blood pressure control and cardiovascular risk reduction.
- Regularly assess renal function and serum electrolytes, especially in high-risk patients (e.g., elderly, renal impairment, heart failure) and during initiation or dose titration.
- Avoid concomitant use with aliskiren in diabetic and renally impaired patients due to increased adverse event risk.
Patient Guidelines
- Take Telmipres exactly as prescribed by your doctor, even if you feel well.
- Do not stop taking the medicine suddenly without consulting your doctor.
- Inform your doctor if you become pregnant or plan to become pregnant while taking this medication.
- Report any unusual side effects, especially swelling of the face, lips, tongue, or throat.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Telmipres may cause dizziness or lightheadedness, especially at the start of treatment or when changing dose. Exercise caution when driving or operating machinery until you know how the medicine affects you.
Lifestyle Advice
- Adopt a healthy lifestyle, including a balanced diet low in sodium and rich in fruits and vegetables.
- Engage in regular physical activity as advised by your doctor.
- Avoid smoking and limit alcohol consumption to help manage blood pressure.
- Monitor your blood pressure at home regularly and keep a record.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Telmipres Brand
Other medicines available under the same brand name
